A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors
Toshiaki Saeki(Saitama Medical University), T Taguchi(Japan Society of Chemotherapy), Atsushi Satoh(Kobe Pharmaceutical University), Shinji Ohno(Unknown), Wasaburo Koizumi(Kitasato University), Masakazu Toi(Mukogawa Women's University), Naohiro Nomura, Akihiko Osaki(Hiroshima University), Tetsuya Toge(Hiroshima University), Masanori Terashima(Shizuoka Cancer Center), Yoshio Fukuyama, Shigemitsu Takashima(National Cancer Center)
Cited by 14
Related Papers
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|2.2k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k